J&J, Pfizer Halt Development of Alzheimer's Drug

Health and Healthcare

Published: August 6, 2012 5:44 pm

Last Updated: April 28, 2020 12:15 am

Johnson & Johnson Inc. (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimer’s after the drug failed a second clinical trial.

The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.

Johnson & Johnson will take a $300 million to $400 million charge in the third quarter.

Shares of Pfizer are down 2.51% in after-hours trading. Shares of Johnson & Johnson are up 0.21%.

Samuel Weigley

Want to Retire Early? Start Here ^(Sponsor)

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.